Cargando cotizaciones...
Previsión
| Comprar |
2 |
| Mantener |
0 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
InMed Pharmaceuticals meets NASDAQ minimum bid-price requirement again
NASDAQ said InMed Pharmaceuticals has met the listing requirement after the closing price of its common stock was at or above $1.00 for ten consecutive trading days from May 19 through last Monday. The exchange has closed the matter; the stock currently trades at $1.56 and, despite a 50% year-to-date increase, remains well below the 52-week high of $5.50. InMed has a market capitalization of $6.96 million and is developing small-molecule drug candidates targeting CB1/CB2 receptors with programs for Alzheimer’s, eye diseases and dermatology. » Más en de.investing.com
InMed Pharmaceuticals files prospectus supplement for at-the-market offering
InMed Pharmaceuticals has filed a prospectus supplement and the related prospectus with the U.S. securities regulator SEC for the sale of common shares under an existing at-the-market agreement with H.C. Wainwright & Co. The filing relies on the S-3 shelf registration that the SEC declared effective on March 30, 2026. The supplement includes a legal opinion from Norton Rose Fulbright Canada LLP on the validity of the offered securities. » Más en de.investing.com
InMed Pharmaceuticals faces delisting after falling below Nasdaq minimum bid price
InMed Pharmaceuticals received a notice from Nasdaq because the stock’s closing price was below $1.00 for 30 consecutive trading days between Feb. 11 and Mar. 26, 2026. The shares currently trade at $0.66 with a market capitalization of $2.59 million; InMed has 180 calendar days to cure the deficiency by achieving a closing price of at least $1.00 for ten consecutive trading days. If the company does not comply, a one-time extension is possible; otherwise delisting is threatened, with a possible appeal to the Nasdaq Hearings Panel. InMed is evaluating options such as a reverse stock split and will monitor the share price. » Más en de.investing.com
InMed Pharmaceuticals reports quarterly loss of $0.43 per share and moderate revenue increase
InMed Pharmaceuticals released results for the quarter ended June 30, 2025: loss per share was $0.43 compared with -$3.80 in the year-ago quarter. Quarterly revenue was $1.3 million (+1.56% year on year). For the full year, loss per share narrowed to $8.36 (prior year -$20.20) on revenue of $4.94 million (+7.39% year on year). » Más en finanzen.net
InMed Pharmaceuticals sets date and record date for 2025 annual general meeting
InMed Pharmaceuticals announced the date, record date and organizational details for its 2025 annual general meeting and filed the information on SEDAR and in a Form 8‑K with the SEC. The company gave no information on agenda items or proposals. It is registered in British Columbia, headquartered in Vancouver; its common shares trade on NASDAQ under the ticker INM; market capitalization is about 4.31 million USD and the stock is down more than 52% year-to-date. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 0 | 100,00 % |
| Beneficio bruto | -195,14 mil | 156,80 % |
| Beneficio neto | -2,06 M | 39,83 % |
| EBITDA | -1,58 M | 18,09 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 7,77 M € |
Número de acciones | 549,37 mil |
Máximo/mínimo de 52 semanas | 21,19 € - 5,23 € |
| Dividendos | No |
Beta | 0,99 |
Ratio P/E | -0,60 |
Ratio PEG | -0,01 |
Ratio P/B | -8,48 |
Ratio P/S | 0,00 |
Perfil de la empresa
InMed Pharmaceuticals Inc., una empresa farmacéutica en fase clínica, investiga y desarrolla terapias basadas en cannabinoides. El producto principal de la compañía es INM-755, una crema tópica de cannabinol que se encuentra en un segundo ensayo clínico de fase I para el tratamiento de la epidermólisis bullosa. La empresa también participa en el desarrollo de INM-088, que se encuentra en estudios preclínicos para el tratamiento del glaucoma; y de INM-405 para el tratamiento del dolor. Además, se dedica al desarrollo de tratamientos basados en cannabinoides para diversas enfermedades, incluidas las dermatológicas y las oculares. Asimismo, la compañía trabaja en estudios de farmacología y toxicología preclínica habilitantes para IND; e IntegraSyn, un enfoque integrado de fabricación basado en biosíntesis, para la síntesis de cannabinoides de calidad farmacéutica. Tiene un acuerdo de colaboración en investigación con BayMedica Inc. para la fabricación y el ensayo de nuevas terapias con cannabinoides. La empresa se conocía anteriormente como Cannabis Technologies Inc. y cambió su nombre a InMed Pharmaceuticals Inc. en octubre de 2014. InMed Pharmaceuticals Inc. fue constituida en 1981 y tiene su sede en Vancouver, Canadá.
| Nombre | InMed Pharmaceuticals |
| CEO | Eric A. Adams Chem. |
| Sede | Vancouver,
bc Canadá |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 05/05/2014 |
| Empleados | 6 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | INM |
Frankfurt | MWG.F |